Evidence map›Paper›PMID 41362453›Full record

ReviewMaterials today. Bio2025

Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy.

Xueqian Xia, Xiang Liu, Yue Gao, Jiatong Lin, Shuangxue Pan, Weijian Cheng, Sheng Huang, Xingyue Liu, Jia-Wei Shen, Wei Duan

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xueqian XiaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Xiang LiuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Yue GaoSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Jiatong LinSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Shuangxue PanSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Weijian ChengSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Sheng HuangSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Xingyue LiuEcology and Health Institute, Hangzhou Vocational & Technical College, Hangzhou, 310032, Zhejiang, China.
Jia-Wei ShenSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Wei DuanSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation poses significant therapeutic challenges due to the limitations of conventional treatments. Nanozymes, merging nanomaterial properties with enzymatic catalysis, offer promising alternatives for inflammation therapy. Among them, metallic nanozymes have attracted considerable attention due to their tunable physicochemical properties and multi-therapeutic potential. However, single-metal nanozymes suffer from insufficient catalytic efficiency, high therapeutic dosage requirements, and limited functionality, which severely hinder their clinical translation. Recent advances in metallic hybrid nanozymes, which integrate the advantages of different metallic elements, have enabled synergistic enhancement of catalytic performance and cascade effects, offering more effective solutions for inflammation treatment. In this review, we first systematically outline the fundamental principles, molecular mechanisms, and current therapeutic approaches for inflammation. Subsequently, we comprehensively discuss the definition, catalytic mechanisms, and rational design strategies of nanozymes, with a focus on the common synthesis methods, activity regulation mechanisms, computer-aided design strategies, and combination therapy approaches for metallic hybrid nanozymes. Furthermore, we provide an in-depth evaluation of the applications of metallic hybrid nanozymes in treating various inflammatory diseases. Finally, we critically analyze the key scientific challenges and future directions in the clinical translation of metallic hybrid nanozymes. This work provides a comprehensive framework for developing next-generation nanozyme therapeutics, bridging fundamental research and clinical applications in inflammation management.

Indexed as

Combined therapyInflammatory diseasesMetallic hybrid nanozymeRational designROS scavenging

Identifiers

PMID41362453
PMCPMC12681884

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.